LAVA Therapeutics NV
General ticker "LVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $38.4M
LAVA Therapeutics NV does not follow the US Stock Market performance with the rate: -13.0%.
Estimated limits based on current volatility of 7.4%: low 0.87$, high 1.01$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.10$, 2.77$]
- 2024-12-30 to 2025-12-30 estimated range: [1.27$, 3.07$]
Financial Metrics affecting the LVTX estimates:
- Negative: Non-GAAP EPS, $ of -1.59 <= 0.10
- Negative: Operating profit margin, % of -86.47 <= 1.03
- Positive: -0.96 < Investing cash flow per share, $ of -0.66
- Negative: Operating cash flow per share per price, % of -48.99 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term LVTX quotes
Long-term LVTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $5.35MM | $19.39MM | $6.77MM |
| Operating Expenses | $48.96MM | $54.23MM | $50.02MM |
| Operating Income | $-43.61MM | $-34.84MM | $-43.25MM |
| Non-Operating Income | $1.42MM | $3.18MM | $1.56MM |
| Interest Expense | $0.62MM | $0.00MM | $0.00MM |
| R&D Expense | $36.95MM | $40.10MM | $33.81MM |
| Income(Loss) | $-42.20MM | $-31.66MM | $-41.70MM |
| Taxes | $0.16MM | $0.25MM | $0.28MM |
| Profit(Loss) | $-42.35MM | $-31.91MM | $-41.97MM |
| Stockholders Equity | $134.19MM | $86.04MM | $51.18MM |
| Inventory | $48.83MM | $0.00MM | $0.00MM |
| Assets | $157.87MM | $143.43MM | $101.71MM |
| Operating Cash Flow | $-32.48MM | $4.04MM | $-38.97MM |
| Capital expenditure | $0.87MM | $0.59MM | $0.73MM |
| Investing Cash Flow | $-49.37MM | $9.35MM | $-17.64MM |
| Financing Cash Flow | $171.37MM | $0.28MM | $-0.57MM |
| Earnings Per Share* | $-2.14 | $-1.23 | $-1.57 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.